November 15 – 16, 2018
New Jersey, USA
Lyophilization is one of the most time-consuming and expensive operations, and improved drying technologies are required for current and future products. 16% of the top 100 pharmaceutical drugs and 35% of biologic drugs are lyophilized, and with more than 30% of the FDA-approved parenterals lyophilized and soon more than half of injectable drugs to require lyophilization, there’s a need for standardization and expansion of the lyophilization process in pharmaceuticals.
SMi’s Lyophilization USA conference will look toward the future of lyophilization. This years’ programme will help participants to discover novel techniques and advances within lyophilization; gain insight into the regulatory challenges in lyophilization and how to overcome these challenges; discuss the current unmet needs within lyophilization and action points needed to address these needs; explore the most recent analytical and other technologies in lyophilization; hear from experts on alternative freeze-drying methods beyond vial lyophilization making Lyophilization USA Conference the perfect platform to strengthen knowledge in key principles.
- Alex Langford, Senior Associate Scientist, Pfizer
- Fabrice Schlegel, Senior Engineer, Amgen
- Rui Fang, Senior Scientist, Merck
- Sushma Kommareddy, Associate Director, Formulation Development, Takeda
- Alina Alexeenko, Professor, Purdue University
Further details at http://www.lyophilization-usa.com/ipiWL
Twitter – @SMIpharm & #lyousa
LinkedIn – SMi Pharma
+44 (0)20 7827 6000